I

    Icecure Medical (ICCM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $2.28
    -0.02 (-0.87%)

    Market Cap: $7.88M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(10/18)
    Avg Surprise
    -7.40%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.83
    Range$-0.83 - $-0.83
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-1.05-26.5%
    60d ago$-1.05-26.5%
    30d ago$-0.88-6.0%
    7d ago$-0.88-6.0%
    Current$-0.83
    Revenue Consensus
    $876500
    Range$850000 - $903000
    2 analysts
    Dec 31, 2026
    EPS Consensus$-2.37
    Range$-2.37 - $-2.37
    1 analysts
    Revenue Consensus
    $623840
    Range$550840 - $696840
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.37---
    Sep 26EST
    		-$-0.83---
    Jun 26
    		$-3.11$-1.37-127.01%Miss-72.8%
    Mar 26
    		$-0.06$-0.05-16.20%Miss+96.8%
    Dec 25
    		$-1.80$-1.20-50.00%Miss-2150.0%
    Sep 25
    		$-1.80$-1.65-9.09%Miss+25.0%
    Jun 25
    		$-1.80$-1.95+7.69%Beat+0.0%
    Mar 25
    		$-1.80$-2.40+25.00%Beat+25.0%
    Dec 24
    		$-0.08$-0.08+0.00%Beat-33.3%
    Sep 24
    		$-2.40$-2.25-6.67%Miss+8.0%
    Jun 24
    		$-1.80$-2.10+14.29%Beat+31.8%
    Mar 24
    		$-2.40$-2.40+0.00%Beat+0.0%
    Dec 23
    		$-0.06$-0.08+21.77%Beat+45.5%
    Sep 23
    		$-2.61$-2.70+3.33%Beat+20.9%
    Jun 23
    		$-2.64$-2.60-1.54%Miss+29.0%
    Mar 23
    		$-2.40$-2.80+14.29%Beat-2100.0%
    Dec 22
    		$-0.11$-0.10-10.00%Miss-21.5%
    Sep 22
    		$-3.30$-3.45+4.35%Beat-4136.2%
    Jun 22
    		$-3.72$-3.60-3.33%Miss-4675.4%
    Mar 22
    		$0.12$0.12+0.00%Beat+263.7%
    Jun 21
    		$-0.09$0.00N/AMiss-0.9%
    Mar 21
    		$-0.08$0.00N/AMiss-46.4%
    Dec 20
    		$-0.08$0.00N/AMiss-46.4%
    Sep 20
    		$-0.07$0.00N/AMiss+7.1%
    Jun 20
    		$-0.09$0.00N/AMiss-14.4%
    Mar 20
    		$-0.05$0.00N/AMiss+43.6%
    Dec 19
    		$-0.05$0.00N/AMiss+42.7%
    Sep 19
    		$-0.08$0.00N/AMiss-3.4%
    Jun 19
    		$-0.08$0.00N/AMiss+10.4%
    Mar 19
    		$-0.09$0.00N/AMiss-9.4%
    Dec 18
    		$-0.09$0.00N/AMiss+16.3%
    Sep 18
    		$-0.08$0.00N/AMiss+37.9%
    Mar 18
    		$-0.09$0.00N/AMiss+21.5%
    Dec 17
    		$-0.09$0.00N/AMiss+97.7%
    Sep 17
    		$-0.11$0.00N/AMiss+10.1%
    Jun 17
    		$-0.12$0.00N/AMiss-
    Mar 17
    		$-0.11$0.00N/AMiss-
    Dec 16
    		$-3.81N/AN/ABeat-
    Sep 16
    		$-0.12$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.34EV/EBITDA-2.63x
    Price/FCF-0.43xFCF Yield-232.87%
    Profitability
    Profit Margin0.00%Operating Margin-487.80%
    ROE-228.30%ROIC-110.42%
    Financial Health
    Debt/Equity0.01xInterest Coverage-106.52x
    Current Ratio2.87xQuick Ratio2.44x
    Trading Statistics
    Beta0.47Avg Volume160.20K
    52-Week High$42.0052-Week Low$2.12

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.37
    SMA 20$2.75
    SMA 50$3.64
    SMA 200$11.97
    EMA 10$2.42
    EMA 20$2.67
    EMA 50$3.65
    EMA 200$11.40

    MACD

    Line: -0.35Signal: -0.36Hist: 0.01

    ADX

    ADX: 17.7+DI: 13.0-DI: 18.7

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down80.0
    PSAR$2.71

    Bollinger Bands

    Upper Band$3.58
    Lower Band$1.92
    %B Position6035%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    32.6

    Momentum Oscillators

    Stoch %K8.3
    Stoch %D8.0
    Williams %R-91.8
    ROC (10d)-19.1%
    Momentum-0.54
    CCI (20d)-84.9
    MFI (14d)8.1

    Volatility Measures

    ATR (14d)$0.37(16.4%)
    StdDev (20d)0.41
    Hist Vol87.0%(High)

    Volume Flow

    VWAP$2.28
    OBV179.3M
    AD Line186.4B
    CMF (20d)-0.123

    Volume Metrics

    Avg Vol (20d)164.6K
    Vol Ratio0.4x(Low)
    VWMA (20d)$2.57

    Pivot Points

    R3$2.53
    R2$2.45
    R1$2.37
    Pivot Point$2.29
    S1$2.21
    S2$2.13
    S3$2.05

    Advanced Oscillators

    TSI-29.61
    Ultimate Osc46.8
    KST-276.89

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$907,000$911,000$1.28M$850,000$525,000$725,000$875,000$662,000$1.01M$743,000$1.25M$327,000
    Cost of Revenue$654,000$616,000$679,000$573,000$394,000$507,000$458,000$427,000$481,000$474,000$686,000$350,000
    Gross Profit$253,000$295,000$600,000$277,000$131,000$218,000$417,000$235,000$530,000$269,000$569,000$-23,000
    Operating Expenses$-4,171,000$4.54M$4.82M$18.20M$3.52M$3.88M$4.94M$4.53M$3.76M$3.92M$4.67M$4.10M
    R&D$2.07M$2.21M$2.30M$1.76M$1.71M$1.66M$1.70M$1.86M$1.58M$1.95M$1.88M$2.20M
    SG&A$1.16M$1.26M$4.54M$1.44M$2.67M$922,000$992,000$918,000$915,000$930,000$2.10M$919,000
    Operating Income$4.42M$-4,247,000$-4,216,000$-17,920,000$-3,385,000$-3,657,000$-4,525,000$-4,293,000$-3,228,000$-3,650,000$-3,415,000$-4,123,000
    Interest Income$0$0$0$0$21,000$69,000$0$0$0$41,000$0$0
    Interest Expense$77,000$27,000$30,000$23,000$0$0$0$0$0$0$0$0
    Income Before Tax$-4,501,000$-4,274,000$-4,246,000$-3,859,000$-3,364,000$-3,588,000$-4,479,000$-4,149,000$-3,081,000$-3,609,000$-2,995,000$-4,000,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$43,558$0$121,586
    Net Income$-4,501,000$-4,274,000$-4,246,000$-3,859,000$-3,364,000$-3,588,000$-4,479,000$-4,149,000$-3,081,000$-3,609,000$-2,995,000$-4,000,000
    EBITDA$-4,353,000$-4,178,000$-4,145,000$-3,763,000$-3,323,000$-3,568,000$-4,443,000$-4,210,000$-3,146,000$-3,691,000N/A$-4,041,000
    EBIT$-4,424,000$-4,247,000$-4,216,000$-3,836,000$-3,385,000$-3,657,000$-4,525,000$-4,293,000$-3,228,000$-3,419,370N/A$-4,121,335
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ICCM

    News

    94% success breast cancer trial backs IceCure (ICCM) in new Dutch distribution push

    IceCure Medical (ICCM) has signed an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands, targeting breast cancer and interventional oncology. This move is supported by the THERMAC trial data, which demonstrated a 94% success rate, 0% complication rate, and 100% treatment tolerance for ProSense® in early-stage breast cancer, leading to its advancement to Phase III with a focus on cryoablation. The partnership aims to enhance market access, clinical education, and physician availability for minimally invasive cryoablation in a strategically important European market.

    Stock Titan•8/24/26•
    Bullish

    IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

    IceCure Medical Ltd. has signed an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands. This agreement aims to expand the commercialization of ProSense® for breast cancer and interventional oncology in a market with strong interest in minimally invasive procedures. The Netherlands is a strategically important market for IceCure, particularly due to the independent THERMAC clinical trial, which evaluated thermal ablation for early-stage breast cancer and has advanced to Phase III focusing on cryoablation after ProSense® showed high complete ablation rates.

    PR Newswire•8/24/26•
    Bullish

    Icecure Medical Ltd. Signs Exclusive Distribution Agreement with Scovas Medical for Prosense Cryoablation Systems in the Netherlands

    Icecure Medical Ltd. has entered into an exclusive distribution agreement with Scovas Medical for its ProSense cryoablation systems in the Netherlands. This agreement focuses on treating breast cancer and other interventional oncology procedures. The partnership aims to support market development, clinical education, and physician access in the Netherlands, a country with strong expertise in interventional radiology.

    www.marketscreener.com•8/24/26•
    Bullish

    IceCure Medical signs exclusive deal to distribute ProSense® cryoablation systems in the Netherlands.

    IceCure Medical has signed an exclusive distribution agreement with Scovas Medical to introduce its ProSense® cryoablation systems in the Netherlands. This partnership aims to expand the use of ProSense® for breast cancer and interventional oncology, leveraging the Netherlands' expertise in interventional radiology and interest in minimally invasive cancer treatments. The collaboration is also supported by the successful Phase III THERMAC trial conducted in the Netherlands, which showed a 94% complete ablation rate for ProSense® cryoablation.

    Pluang•8/24/26•
    Bullish

    IceCure Medical (ICCM): Commercial Adoption Is Improving, but the Reimbursement and Scale Story Still Needs More Proof

    IceCure Medical (ICCM) reported a 45% revenue increase in the first half of 2026, driven by stronger commercial adoption of its ProSense system after FDA clearance for low-risk breast cancer. The company's strategy focuses on a self-reinforcing cycle where commercialization boosts clinical usage, leading to improved physician confidence and reimbursement. Investors should monitor whether install-base growth translates to recurring revenue, the progress of the CHoICE study for clinical evidence and reimbursement, and the company's capital management given its ongoing spending on R&D and commercial expansion.

    AlphaStreet•8/21/26•
    Somewhat-Bullish

    Frequently Asked Questions About ICCM

    Does ICCM pay dividends?
    Icecure Medical (ICCM) does not currently pay a regular dividend.
    What is ICCM's market cap?
    Icecure Medical (ICCM) has a market capitalization of $7.88M with a current stock price of $2.28.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In